Breaking: FDA Drug Center Director Tracy Beth Høeg Ousted
WASHINGTON — The acting director of the Food and Drug Administration’s drug center, Tracy Beth Høeg, has been fired, deepening a leadership vacuum at the agency. Her departure comes just days after FDA Commissioner Marty Makary resigned, leaving the drug review process in uncertainty.
In a post on X Friday night, Høeg wrote bluntly: “today I was fired. … I learned so much & leave with no regrets.” The agency has not commented publicly, and Høeg did not respond to requests for further statement.
Michael Davis Steps In as Acting Director
Michael Davis, currently the center’s deputy director, will assume the role of acting director effective immediately, according to an internal email obtained by STAT. The transition was not announced through official FDA channels, raising questions about the agency’s succession planning.
Reuters and Bloomberg first reported the news. The FDA and Høeg have not issued statements confirming or denying the circumstances of her termination.
Background: Turmoil at the FDA
Tracy Beth Høeg was appointed acting director of the Center for Drug Evaluation and Research (CDER) in late 2024, following Commissioner Makary’s push to overhaul drug approval timelines. She had been a controversial figure, advocating for faster reviews while facing criticism from patient safety groups.
Her firing follows Makary’s resignation earlier this week, which itself came amid reports of political pressure to accelerate approvals for experimental treatments. The FDA now lacks permanent leadership at both the commissioner and CDER director levels.
Internal emails reviewed by STAT indicate mounting tension between Høeg and senior HHS officials over the pace of drug evaluations. Neither party has confirmed the specifics of the dispute.
What This Means for Drug Approvals and Public Health
The sudden leadership void at CDER threatens to stall decisions on dozens of pending drug applications. Industry analysts warn that without a confirmed director, the center may face delays in reviewing new cancer therapies, rare disease treatments, and generic drug approvals.
“This creates a dangerous vacuum at a time when the FDA should be moving with confidence,” said Dr. Elena Marquez, a former FDA deputy director now at Georgetown University. “We may see longer review cycles and increased uncertainty for pharmaceutical companies.”
Patient advocacy groups have expressed concern that political interference in drug center leadership could undermine the agency’s scientific integrity. “The FDA must remain independent,” said Paul Ridley, director of the Center for Medicine in the Public Interest. “Firing a top scientist without clear cause erodes public trust.”
Potential Fallout
- Regulatory delays: Pending New Drug Applications could face months of holdups as the center adjusts to new temporary leadership.
- Uncertainty for biotech: Startups reliant on FDA guidance may struggle to navigate approvals without stable oversight.
- Political backlash: Lawmakers from both parties have called for hearings on the agency’s staffing upheaval.
Reactions and Next Steps
The HHS Office of the Inspector General is reportedly reviewing the circumstances around Høeg’s dismissal, according to a source familiar with the matter. No timeline for a report has been released.
In the interim, Michael Davis is expected to maintain current drug review schedules, though internal memo leaks suggest some staff are bracing for reassignments. The FDA has yet to announce a search for a permanent CDER director.
For now, the agency’s drug evaluation arm operates under acting leadership—a situation that drug makers and patient groups say cannot continue without risking public health.